Oxford BioDynamics (AIM:OBD) has secured its first commercial agreement for EpiSwitch Orion, marking the first time a third party has paid for access to the cloud-based 3D genomics platform.
The AIM-listed biotech, which develops precision diagnostic tests for personalised healthcare, will be paid for both laboratory biomarker discovery work and for processing genomic data using Orion.
The deal sits within OPTIMISE, a translational research programme funded by the UK Department of Health and Social Care via the National Institute for Health and Care Research, run in partnership with the University of Oxford's NDORMS, the University of Glasgow, King's College London and Guy's and St Thomas' NHS Foundation Trust.
The programme draws on samples from 240 psoriatic arthritis patients randomised to secukinumab or adalimumab therapy, aiming to identify blood-based biomarkers that predict which patients will respond to which biologic drug.
One strand uses OBD's EpiSwitch 1M whole-genome array to build a qPCR classifier for secukinumab response; a second applies Orion and machine learning across roughly 240 whole-genome sequenced samples to model response to both drug classes.
"This deal reflects the growing recognition of the platform's potential across the research community", said chief executive Richard Compton, adding that OBD estimates roughly 15,000 genomics principal investigators globally hold samples and funding that could use the platform.
Financial terms were not disclosed.
OBD said it would update on commercial progress in its scheduled financial reporting.
News Intelligence what this means for the company
Oxford BioDynamics has signed its first paid commercial agreement for EpiSwitch Orion, its cloud-based 3D genomics platform, under the UK-funded OPTIMISE psoriatic arthritis biomarker programme. The deal validates the platform's commercial viability beyond internal R&D and positions OBD to monetise access to its technology across a potential market of roughly 15,000 genomics principal investigators globally—a material expansion of the company's revenue model beyond its existing diagnostic test business.
This marks the first third-party validation of Orion's commercial appeal and demonstrates a new revenue stream (platform licensing and data processing fees) distinct from the company's diagnostic test sales. However, undisclosed financial terms and the absence of guidance on deal size or expected recurring revenue limit visibility into the material impact on near-term earnings.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
